Last reviewed · How we verify
Immediate switch to TDF/FTC/RPV
A fixed-dose combination of three antiretroviral agents that inhibits HIV reverse transcriptase and integrase to suppress viral replication.
A fixed-dose combination of three antiretroviral agents that inhibits HIV reverse transcriptase and integrase to suppress viral replication. Used for HIV-1 infection in treatment-naive or treatment-experienced adults.
At a glance
| Generic name | Immediate switch to TDF/FTC/RPV |
|---|---|
| Also known as | Eviplera (r) |
| Sponsor | Azienda Ospedaliera San Gerardo di Monza |
| Drug class | Antiretroviral combination therapy (NRTI/NNRTI) |
| Target | HIV reverse transcriptase, HIV integrase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
TDF (tenofovir disoproxil fumarate) is a nucleotide reverse transcriptase inhibitor, FTC (emtricitabine) is a nucleoside reverse transcriptase inhibitor, and RPV (rilpivirine) is a non-nucleoside reverse transcriptase inhibitor. Together they target different mechanisms of HIV replication, reducing viral load in treatment-experienced or treatment-naive patients.
Approved indications
- HIV-1 infection in treatment-naive or treatment-experienced adults
Common side effects
- Nausea
- Diarrhea
- Headache
- Rash
- Renal impairment (TDF-related)
- Bone density loss (TDF-related)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: